Literature DB >> 7386310

Action of gold salts in some inflammatory and immunological models.

A J Lewis, J Cottney, D D White, P K Fox, A McNeillie, J Dunlop, W E Smith, D H Brown.   

Abstract

Several gold salts were compared in kaolin-induced rat paw oedema, u.v. erythema in guinea pigs, delayed type hypersensitivity and humoral immunity in mice, and adjuvant-induced arthritis in the rat. In the latter the additional parameters of serum gold and copper levels and lysosomal enzyme activity were determined. In addition, the in vitro inhibition of several lysosomal enzymes derived from mouse macrophages was studied. The gold compounds examined were aurothiomalate, aurothioglucose, triethylphosphine gold chloride (SK & F 36914) and its glucopyranoside derivative (SK & F D-39162), triphenylphosphine gold chloride and sodium gold chloride dihydrate. SK & F 36914 and SK & F D-39162 has significant activity after oral dosage upon paw kaolin and u.v. erythema in rats and guinea pigs, respectively. Gastric swelling also occurred. In Wistar rats, adjuvant arthritis was little affected by the gold salts but in the Lewis rats there was suppression. In both strains there was less elevation in serum copper levels with treatment by SK & F 36914 and SK & F D-39162, but not by aurothiomalate. None of the compounds had any measurable effect on delayed hypersensitivity or humoral antibody levels in mice. The in vitro activities of cathepsin B1 and cathepsin D were inhibited by all the gold compounds. Reactivity of gold compounds with glutathione and cysteine in vitro was dependent on compound solubility and the nature of the gold ligand. Considerable differences exist between the profiles of activity for the different gold salts evaluated. These observations indicate that some gold salts do possess anti-inflammatory activity with a potency similar to that of indomethacin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7386310     DOI: 10.1007/bf02024180

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  61 in total

1.  PRESENCE OF GLUCOSAMINIDASE ACTIVITY IN HUMAN SYNOVIAL FLUID AND ITS INHIBITION BY GOLD COMPOUNDS.

Authors:  J C CAYGILL; F R JEVONS
Journal:  Clin Chim Acta       Date:  1965-03       Impact factor: 3.786

2.  Serum copper and its relationship to clinical symptoms in rheumatoid arthritis.

Authors:  D H Brown; W W Buchanan; A F el-Ghobarey; W E Smith; J Teape
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

3.  Effect of gold salts and other drugs on the release and activity of lysosomal hydrolases.

Authors:  R S Ennis; J L Granda; A S Posner
Journal:  Arthritis Rheum       Date:  1968-12

4.  Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes.

Authors:  B M Sutton; E McGusty; D T Walz; M J DiMartino
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

5.  Evans blue-carrageenan pleural effusion as a model for the assay of nonsteroidal antirheumatic drugs.

Authors:  L F Sancilio
Journal:  J Pharmacol Exp Ther       Date:  1969-07       Impact factor: 4.030

6.  The effects of antiinflammatory drugs on the production of prostaglandins in vivo.

Authors:  G A Higgs; E A Harvey; S H Ferreira; J R Vane
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

7.  In vitro inhibition of the biosynthesis of a prostaglandin by gold and silver.

Authors:  C Deby; Z M Bacq; D Simon
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

8.  Influence of antirheumatic agents on the release of histamine from rat peritoneal mast cells after an antigen-antibody reaction.

Authors:  S Norn
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1965

9.  Lysosomal enzyme levels in the blood of arthritic rats.

Authors:  A J Collins; D A Lewis
Journal:  Biochem Pharmacol       Date:  1971-01       Impact factor: 5.858

10.  Selective inhibition of prostaglandin biosynthesis by gold salts and phenylbutazone.

Authors:  K J Stone; S J Mather; P P Gibson
Journal:  Prostaglandins       Date:  1975-08
View more
  8 in total

1.  Effects of gold sodium thiomalate, cyclosporin A, cyclophosphamide, and placebo on collagen-induced arthritis in rats.

Authors:  G W Cannon; S McCall; B C Cole; L A Radov; J R Ward; M M Griffiths
Journal:  Agents Actions       Date:  1993-03

2.  Anti-inflammatory effects of recombinant human manganese superoxide dismutase on adjuvant arthritis in rats.

Authors:  M Shingu; S Takahashi; M Ito; N Hamamatu; Y Suenaga; Y Ichibangase; M Nobunaga
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

3.  Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat.

Authors:  G Engelhardt; D Homma; C Schnitzler
Journal:  Inflamm Res       Date:  1995-12       Impact factor: 4.575

4.  Auranofin in the treatment of steroid dependent asthma: a double blind study.

Authors:  G Nierop; W P Gijzel; E H Bel; A H Zwinderman; J H Dijkman
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach.

Authors:  Aleksandra M Bondžić; Mirjana B Čolović; Goran V Janjić; Božidarka Zarić; Sandra Petrović; Danijela Z Krstić; Tiziano Marzo; Luigi Messori; Vesna M Vasić
Journal:  J Biol Inorg Chem       Date:  2017-04-21       Impact factor: 3.358

7.  Effect of gold salts, D-penicillamine and benoxaprofen on type II collagen-induced arthritis in rats.

Authors:  A J Lewis; R P Carlson; J Chang; F DeLustro
Journal:  Agents Actions       Date:  1984-06

8.  In vitro and in vivo effects of gold salts on chemotaxis and random migration of rat polymorphonuclear leucocytes.

Authors:  D Pham Huy; M Roch-Arveiller; O Muntaner; J P Giroud
Journal:  Agents Actions       Date:  1985-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.